Mechanisms of tumor vascular shutdown induced by 5,6‐dimethylxanthenone‐4‐acetic acid (DMXAA): Increased tumor vascular permeability
Open Access
- 30 March 2005
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 116 (2) , 322-326
Abstract
The novel vascular targeting agent 5,6‐dimethylxanthenone‐4‐acetic acid (DMXAA) has completed phase 1 clinical trial and has shown tumor antivascular activity in both mice and humans. We have investigated its ability to change tumor vascular permeability, relating it to tumor vascular perfusion and other responses. The murine colon 38 adenocarcinoma was grown in C57Bl wild‐type mice and mice lacking expression of either tumor necrosis factor receptor‐1 (TNFR1−/−) or TNF (TNF−/−). Tumor vascular permeability, as measured by extravasation of albumin‐Evans Blue complexes 4 hr after DMXAA treatment, was significantly increased in tumor tissue in C57Bl, TNFR1−/− and TNF−/− mice but not in normal (skin) tissue. Significant linear relationships were found between increased tumor vascular permeability, decreased functioning tumor blood vessels (measured by Hoechst 33342 staining at 4 hr), increased plasma 5‐hydroxyindole‐3‐acetic acid concentrations (as a measure of serotonin release by platelets) and the degree of induced tumor hemorrhagic necrosis. The results support the hypothesis that DMXAA increases tumor vascular permeability both directly and through the induction of other vasoactive mediators, including TNF. DMXAA might be useful clinically to potentiate the vascular permeability of other anticancer modalities such as cytotoxic drugs, antibodies, drug conjugates and gene therapy.Keywords
This publication has 27 references indexed in Scilit:
- Modulation of thalidomide pharmacokinetics by cyclophosphamide or 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice: the role of tumour necrosis factorCancer Chemotherapy and Pharmacology, 2004
- MRI for assessing antivascular cancer treatmentsBritish Journal of Radiology, 2003
- Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA)Cancer Chemotherapy and Pharmacology, 2003
- Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissuesInternational Journal of Radiation Biology, 2001
- Effects of protein binding on the in vitro activity of antitumour acridine derivatives and related anticancer drugsCancer Chemotherapy and Pharmacology, 2000
- Increased permeability of primary cultured brain microvessel endothelial cell monolayers following TNF-α exposureLife Sciences, 1999
- Vesiculo-vacuolar organelles and the regulation of venule permeability to macromolecules by vascular permeability factor, histamine, and serotonin.Journal of Experimental Medicine, 1996
- The morphological effects of the anti–tumor agents flavone acetic acid and 5,6–dimethyl xanthenone acetic acid on the colon 38 mouse tumorPathology, 1994
- Potential antitumor agents. 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acidsJournal of Medicinal Chemistry, 1991
- Comparison of the effects of flavone acetic acid, fostriecin, homoharringtonine and tumour necrosis factor α on Colon 38 tumours in miceEuropean Journal of Cancer and Clinical Oncology, 1989